Oliver Lagore Vanvalin Investment Group Avidity Biosciences, Inc. Transaction History
Oliver Lagore Vanvalin Investment Group
- $370 Million
- Q4 2024
A detailed history of Oliver Lagore Vanvalin Investment Group transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Oliver Lagore Vanvalin Investment Group holds 663 shares of RNA stock, worth $20,950. This represents 0.01% of its overall portfolio holdings.
Number of Shares
663
Previous 1,754
62.2%
Holding current value
$20,950
Previous $80,000
76.25%
% of portfolio
0.01%
Previous 0.02%
Shares
3 transactions
Others Institutions Holding RNA
# of Institutions
257Shares Held
100MCall Options Held
517KPut Options Held
717K-
Price T Rowe Associates Inc Baltimore, MD11MShares$349 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.43MShares$298 Million0.0% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$272 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY7.93MShares$251 Million3.76% of portfolio
-
Avoro Capital Advisors LLC New York, NY7.5MShares$237 Million3.18% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.65B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...